Next-generation psychedelic and cannabinoid medicines
Enveric’s CBD molecules target radiodermatitis, glioblastoma multiforme (GBM) and chemotherapy-induced neuropathy. Phase 1 clinical trials are scheduled to begin in 2022 to test if CBD lowers the required dose of chemotherapy in GBM patients while maintaining efficacy, resulting in fewer debilitating side effects and a higher quality of life.
Discovering Next-generation Treatments for the Mind and Body
Our mission is to improve the characteristics of psychedelic- and cannabinoid-derived pharmaceuticals by unlocking their full potential to create treatment solutions for a growing and underserved patient population.